Sandoz Announces Leadership Transition as Francisco Ballester Retires
Francisco Ballester to retire as Sandoz President Region International; Peter Stenico appointed successor.
Breaking News
Feb 03, 2025
Mrudula Kulkarni

Sandoz, a global leader in generic and biosimilar medicines, has announced that Francisco Ballester, President Region International and a member of the Sandoz Executive Committee (SEC), will retire on March 1, 2025. Since 2019, Francisco has led business growth and patient access across markets outside North America and Europe, while nurturing a highly diverse talent pool. With over three decades of service at Sandoz, his leadership has left a lasting impact on the company’s international strategy.
Peter Stenico, currently Global Platform Head, Biosimilars, will step into the role. Having joined Sandoz in 2002, Peter has extensive experience in biosimilars and generics, having previously served as Country Head and General Manager for Sandoz Germany and as President of the German Generics Association (Pro Generika). His strategic expertise in M&A, commercial operations, and global biosimilar leadership positions him well to drive growth in the Region International markets.
Richard Saynor, CEO of Sandoz, expressed gratitude for Francisco’s long-standing contributions, stating, “Francisco spent over three decades demonstrating focus, passion, and dedication to our business and people. I wish him the very best in his retirement.” He also welcomed Peter Stenico, emphasizing his deep industry knowledge and strong leadership background as key assets in advancing Sandoz’s regional growth strategy.